A search for new metabolites of N,N',N''-triethylenethiophosphoramide

Cancer Research

Volumn 59, Issue 18, 1999, Pages 4720-4724

  Van Maanen, Maria J ^a,b   Tijhof, Inge M ^a   Damen, J Mirjam A ^a   Versluis, Cees ^a   Ketteness Van Den Bosch, Jantien J ^a   Heck, Albert J R ^a   Rodenhuis, Sjoerd ^c   Beijnen, Jos H ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DRUG METABOLITE; N,N' DIETHYLENE N'' 2 CHLOROETHYLPHOSPHORAMIDE; TEPA; THIOTEPA; THIOTEPA MERCAPTURATE; UNCLASSIFIED DRUG;

ALKYLATION; ANALYTIC METHOD; ARTICLE; DRUG CONJUGATION; DRUG DETERMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG STRUCTURE; GLUTATHIONE METABOLISM; PRIORITY JOURNAL; STRUCTURE ANALYSIS; URINALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MIDDLE AGED; MOLECULAR STRUCTURE; THIOTEPA;

EID: 0033567896     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sykes, M., Karnovsky, D., Phillips, F., and Burchenal, J. Clinical studies of triethylenephosphoramide and diethylenephosphoramide compounds with nitrogen mustard-like activity. Cancer (Phila.), 6: 142-148, 1953.
2. Van der Wall, E., Beijnen, J. H., and Rodenhuis, S. High-dose chemotherapy regimens for solid tumors. Cancer Treat. Rev., 21: 105-132, 1995.
3. Mellet, L. B., and Woods, L. A. The comparative physiological disposition of thioTEPA and TEPA in the dog. Cancer Res., 20: 524-532, 1950.
4. Chang, T. K. H., Chen, G., and Waxman, D. J. Modulation of thioTEPA antitumor-activity in-vivo by alteration of liver cytochrome P450-catalyzed drug-metabolism. J. Pharmacol. Exp. Ther., 274: 270-275, 1995.
5. Ng, S. F., and Waxman, D. J. Biotransformation of N, N′, N″-triethylenethiophosphoramide: oxidative desulfuration to yield N, N′, N″-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. Cancer Res., 50: 464-471, 1990.
6. Egorin, M. J., Snyder, S. W., Pan, S., and Daly, C. Cellular transport and accumulation of thioTEPA in murine, human and avian cells. Cancer Res., 49: 5611-5617, 1989.
7. Egorin, M. J., Snyder, S. W., and Wietharn, B. E. Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells. Cancer Res., 50: 4322-4327, 1990.
8. Egorin, M. J., Cohen, B. E., Kohlhepp, E. A., and Gutierrez, P. L. Gas-liquid Chromatographic analysis of N, N′ ,N″-triethylenethiophosphoramide and N, N′ ,N″-triethylenephosphoramide in biological samples. J. Chromatogr., 343: 196-202, 1985.
9. McDermott, B. J., Double, J. A., Bibby, M. C., Wilman, D. E. V., Loadman, P. M., and Turner, R. L. Gas chromatographic analysis of triethylenephosphoramide and triethylenethiophosphoramide in biological specimen. J. Chromatogr., 338: 335-345, 1985.
10. Masters, J. R. W., McDermott, B. J., Harland, S., Bibby, M. C., and Loadman, P. M. ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Cancer Chemother. Pharmacol., 38: 59-64, 1996.
11. Cohen, B. E., Egorin, M. J., Kohlhepp, E. A., Aisner, J., and Gutierrez, P. L. Human plasma pharmacokinetics and urinary excretion of thioTEPA and its metabolites. Cancer Treat. Rep., 70: 859-864, 1986.
12. Hagen, B., Neverdal, G., Walstad, R. A., and Nilsen, O. G. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients. Cancer Chemother. Pharmacol., 25: 257-262, 1990.
13. Hagen, B. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects. Cancer Chemother. Pharmacol., 27: 373-378, 1991.
14. 32P-labelled triethylenephosphoramide in relation to its anti-tumour activity. Br. J. Pharmacol., 10: 321-325, 1955.
15. 14C-labeled N, N′, N″-triethylenethiophosphoramide (thio-TEPA) in humans and dogs. J. Lab. Clin. Med., 60: 818-825, 1962.
16. Van der Wall, E., Richel, R. J., Kusumanto, Y. H., Rutgers, E., Schornagel, J. H., Schaake-Koning, C. C. E., Peterse, J. L., and Rodenhuis, S. Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. Ann. Oncol., 4: 791-792, 1993.
17. Rodenhuis, S., Westermann, A., Holtkamp M. J., Nooijen, W. J., Baars, J. W., Van der Wall, E., Slaper-Cortenbach, I. C. M., and Schornagel, J. H. Feasibility of multiple courses of high-dose cyclophosphamide, thioTEPA and carboplatin for breast cancer or germ cell cancer. J. Clin. Oncol., 14: 1473-1483, 1996.
18. van Maanen, R. J., van Ooijen, R. D., Zwikker, J. W., Huitema, A. D. R., Rodenhuis, S., and Beijnen, J. H. Determination of thioTEPA and its active metabolite TEPA in plasma and urine using capillary gas chromatography. J. Chromatogr. B, 719: 103-112, 1998.
19. Friedman, O. M., and Boger, E. Colorimetric estimation of nitrogen mustards in aqueous media: hydrolytic behavior of bis(β-chloroethyl)amine, nor HN2. Anal. Chem., 33: 906-910, 1961.
20. Braggio, S., Barnaby, R. J., Grossi, P., and Cugola, M. A strategy for the validation of bioanalytical methods. J. Pharmacol. Biomed. Anal., 14: 375-388, 1996.
21. Pyatigorskaya, T. L., Zhilkova, O. Y., Shelkovsky, V. S., Arkhangelova, N. M., Grizodub, A. I., and Sukhodub, L. F. Hydrolysis of l,l′,l″-phosphinothioylidinetrisaziridine (thioTEPA) in aqueous solution. Biomed. Environ. Mass Spectrom., 14: 143-148, 1987.
22. 1H-NMR study. Biochem. Pharmacol., 25: 989-992, 1976.
23. van Maanen, M. J., Brandt, A. C., Damen, J. M. A., and Beijnen, J. H. Degradation study of thioTEPA in aqueous solutions. Int. J. Pharm., 179: 55-64, 1999.
24. Dirven, H. A. A. M., Dictus, E. L. J. T., Broeders, N. L. H. L., Vanommen, B., and van Bladeren, P. J. The role of human glutathione-S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thioTEPA. Cancer Res., 55: 1701-1706, 1995.
25. Cohen, B. E., Egorin, M. J., Nayar, M. S. B., and Gutierrez, P. L. Effects of pH and temperature on the stability and decomposition of N, N′, N″-triethylenethiophosphoramide in urine and buffer. Cancer Res., 44: 4312-4316, 1984.
26. Cnubben, N. H. P., Rommens, A. J. M., Oudshoorn, M. J., and van Bladeren, P. J. Glutathione-dependent biotransformation of the alkylating drug thioTEPA and transport of its metabolite monoglutathionylthioTEPA in human MCF-7 breast cancer cells. Cancer Res., 58: 4616-4623, 1998.
27. Gibson, G. G., and Skett, P. Introduction to Drug Metabolism, pp. 1-37. London: Chapman and Hall, 1986.
28. Chasseaud, L. F. Conjugation with glutathione and mercapturic acid excretion. In: I. M. Arias and W. B. Jakoby (eds.), Glutathione: Metabolism and function, pp. 77-114. New York: Raven Press, 1976.
29. Brakenhoff, J. P. G., Commandeur, J. N. M., Lamoree, M. H., Dubbelaar, A. C., van Baar, B. L. M., Lucas, C., and Vermeulen, N. P. E. Identification and quantitative determination of glutathione-related urinary metabolites of fotemustine, a new anti-cancer agent. Xenobiotica, 23: 935-947, 1993.
30. Elfarra, A. A., Sharer, J. E., and Duesher, R. J. Synthesis and characterization of N-acetyl-I-cysteine S-conjugates of butadiene monoxide and their detection and quantification in urine of rats and mice given butadiene monoxide. Chem. Res. Toxicol., 8: 68-76, 1995.